NCT03520660 2026-03-11
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Phase 4 Active not recruiting
Clinical Trials
5 trialsNCT02959359 2017-08-07
DAA in the Risk of Recurrence After Curative Treatment of HCC
Taipei Veterans General Hospital, Taiwan
Phase 4 Withdrawn
NCT00630084 2015-09-04
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4 Completed
NCT00375661 2015-09-02
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Kyoto University Hospital
Phase 4 Completed
NCT00834860 2010-02-15
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4 Unknown